<DOC>
	<DOC>NCT01301313</DOC>
	<brief_summary>To evaluate the efficacy and safety of levosimendan versus conventional intensified inotropic treatment, in critical children with severe acute heart failure which persists despite of having received conventional inotropic treatment.</brief_summary>
	<brief_title>Efficacy and Safety of Levosimendan in Severe Acute Heart Failure in Critical Children</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Simendan</mesh_term>
	<criteria>Patients who give written consent to participate in the study and for the transfer of material for cellular and molecular studies. Understand the purpose of the study and to be available to perform the procedures written in the protocol. Any child of 1 day old to 18 years old, admitted to the Paediatric Intensive Care Unit due to severe acute heart failure of any etiology. All patients who express their wish of not to participate in the protocol have hypertrophic or restrictive cardiomyopathy have aortic Stenosis have a known allergy to any drug used in the study it is not possible to prescribe the study medication because it is contraindicated according to the Summary of the Product Characteristic or according to the criteria of the physician responsible for patient are pregnant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Acute heart failure</keyword>
	<keyword>Children</keyword>
	<keyword>Levosimendan</keyword>
	<keyword>Inotropic treatment</keyword>
</DOC>